Galapagos Biopharma Germany GmbH
Pharmaceutical Companies · München
Galapagos Biopharma Germany GmbH is a pharmaceutical company based in München, Bavaria, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Galapagos Biopharma Germany GmbH Address & Contact
Company profile
1999
Founded
2.000+
Employees
Galapagos Biopharma Germany GmbH Overview
Galapagos Biopharma Germany GmbH is the German subsidiary of the Belgian biotechnology company Galapagos NV, which specializes in the discovery and development of innovative therapies for inflammatory diseases and other hard-to-treat conditions. The German company is based in Munich and plays a central role in the development of new therapeutic solutions within the Galapagos group. The company is committed to improving the quality of life for patients by developing tailored treatment approaches that meet the needs of patients with chronic diseases.
Inflammation Therapies and Rheumatology
Galapagos is primarily known in Germany for the JAK-1 inhibitor Filgotinib (Jyseleca). This drug is approved for the treatment of rheumatoid arthritis and ulcerative colitis and has proven effective in alleviating symptoms and improving quality of life. Furthermore, the company is intensively researching new therapeutic approaches for fibrosis, Crohn's disease, and other chronic inflammatory conditions. Filgotinib represents a significant advancement in rheumatological therapy and enhances the application of targeted therapies that directly intervene in the molecular processes of the diseases. The partnership with Gilead Sciences significantly expands Galapagos' global development and marketing capacity and facilitates an informed exchange of clinical data and market strategies.
Product Areas and Regulatory Classification
Galapagos' product range spans several therapeutic areas, focusing on inflammatory diseases as well as immunological and dermatological conditions. In addition to Filgotinib, the company is also investigating advanced treatment approaches in the development of drugs that target various signaling pathways in the body. The regulatory classification of the products is carried out in accordance with the guidelines of the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the USA, which impose strict requirements on safety and efficacy. These regulatory processes are crucial to ensuring the quality of the therapies and providing patients with safe and effective treatment options.
Location Munich
From Munich, Galapagos Biopharma Germany supports rheumatologists, gastroenterologists, and inflammation medicine centers in Germany. Munich, as one of Germany's leading biotech locations, offers not only excellent research infrastructure but also an active network of professionals and institutions. Proximity to renowned clinics and research institutions allows for close collaboration on clinical trials and the execution of research projects. These regional characteristics promote knowledge transfer and support Galapagos in bringing innovative solutions to market that are based on the latest scientific findings.
Features of the Corporate Strategy
Galapagos pursues a clear corporate strategy focused on the continuous improvement of therapeutic outcomes. The company relies on an integrated pipeline strategy that encompasses research, development, and marketing. Through targeted investments in clinical studies and partnerships with leading academics, the knowledge about inflammatory diseases is continuously expanded. Close collaboration with companies like Gilead Sciences and medical research institutions makes Galapagos an important player in the field of biopharmaceutical technologies. The commitment to developing sustainable therapies tailored to the specific needs of patients is central to the corporate philosophy.
More pharmaceutical companies in Germany | pharmaceutical companies in Munich | pharmaceutical companies in Bavaria
Frequently asked questions about Galapagos Biopharma Germany GmbH
What does Galapagos Biopharma Germany do?
Galapagos Biopharma Germany GmbH is ein Biotechnologieundernehmen, the after neuen Wirkmechanismen of medicinesn sucht, um Behandlungsmöglichkeiten zu verbessern. Therapiegebiete are hauptsächlich entzündliche Erkrankungen, Fibrose, Antiinfektiva and Stoffwechselerkrankungen. Daat forschen sie on dem Gebiet the Fehlfunktionen bestimmter Proteine.
More Pharmaceutical Companies in München
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.